Clinical Trial

Exocrine-Endocrine Pancreatic Crosstalk: Precision Pathways to Reframe Diabetes Pathophysiology

Study acronym: EXPAND
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The EXPAND study is a prospective observational study designed to investigate the biological mechanisms underlying the heterogeneity of type 2 diabetes and related metabolic disorders. The study will enroll adults with and without pancreatic disease, including patients undergoing pancreatic surgery, individuals with chronic pancreatitis, subjects at high risk of type 2 diabetes, and patients with newly diagnosed type 2 diabetes. Clinical, metabolic, imaging, genetic, microbiome, and molecular data will be integrated to identify distinct metabolic endotypes and to investigate the interactions between the exocrine pancreas, endocrine pancreas, and adipose tissue. The ultimate goal is to improve the understanding of diabetes pathophysiology and support the development of precision medicine approaches.
Trial Details
NCT Number NCT07670871
Lead Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions Type 2 Diabetes Mellitus (T2DM), Chronic Pancreatitis, Prediabetes, Pancreatic Neoplasms
Enrollment 440 participants
Start Date 2026-09
Primary Completion 2029-11 (estimated)
Study Completion 2031-09 (estimated)
Updated on ClinicalTrials.gov 2026-06-26